(Q39411080)

11 September 2017

title

Minocycline inhibits growth of epithelial ovarian cancer (English)

1 reference

11 September 2017

1 reference

1 reference

Mohammad H Pourgholami

1

1 reference

11 September 2017

Ahmed H Mekkawy

2

1 reference

11 September 2017

Samina Badar

3

1 reference

11 September 2017

David L Morris

4

1 reference

11 September 2017

language of work or name

English

0 references

publication date

16 January 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

125

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

433-440

1 reference

The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Promising molecular targets in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Achievements and unmet needs in the management of advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Chemotherapy: A new standard combination for recurrent ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

A 15-month evaluation of the effects of repeated subgingival minocycline in chronic adult periodontitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Prospects for minocycline neuroprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline as a neuroprotective agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline and neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

The antitumour effect of doxycycline on a T-cell leukaemia in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

A comparison of the bloavailability of minocydline capsules and film-coated tablets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Absorption of minocycline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline excretion and distribution in relation to renal function in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Pharmacokinetic studies on minocycline in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline inhibits apoptotic cell death in a murine model of partial flap loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Alternate splicing in a parvoviral nonstructural gene links a common amino-terminal sequence to downstream domains which confer radically different localization and turnover characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Administration of minocycline ameliorates damage in a renal ischemia/reperfusion injury model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Impairment of mitochondrial function by minocycline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Proliferation, cell cycle and apoptosis in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Morphologic effects of minocycline in laboratory animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Therapeutic evaluation of minocycline and tetracycline for mixed anaerobic infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.01.006

10.1016/J.YGYNO.2012.01.006

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference